Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Vaccinations01:51

Vaccinations

Overview

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Onasemnogene Abeparvovec in Patients With SMA: Interim Results of the RESTORE Registry in Japan.

Annals of clinical and translational neurology·2026
Same author

Informing life-course immunization and pandemic preparedness: a COVID-19 vaccine evaluation and HPV introduction experience in Sierra Leone.

BMC public health·2026
Same author

Post-Transcatheter Aortic Valve Replacement Acute Severe Mitral Regurgitation: A Case Report.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2026
Same author

"Things Fall Apart": The Unravelling of Global Health Governance and the Imperative for Action Preserving Infectious Disease Prevention and Control.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026
Same author

Sotatercept for pulmonary arterial hypertension on background therapy: a systematic review and meta-analysis of randomized controlled trials.

Proceedings (Baylor University. Medical Center)·2025
Same author

Myocardial Infarction in a Patient With Homozygous Plasminogen Activator Inhibitor-1 (PAI-1) 4G/4G Mutation: A Case Report.

Cureus·2025

Related Experiment Video

Updated: May 27, 2026

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
13:47

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

Financial impact to providers using pediatric combination vaccines.

Angela K Shen1, Elizabeth Sobczyk, Lone Simonsen

  • 1National Vaccine Program Office, US Department of Health andHuman Services, Washington, DC, USA.

Pediatrics
|November 23, 2011
PubMed
Summary

Pediatric providers receive lower payments for using combination vaccines like Pediarix compared to individual component vaccines. Monitoring immunization administration codes is crucial to address financial barriers for combination vaccine use.

More Related Videos

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Related Experiment Videos

Last Updated: May 27, 2026

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
13:47

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Area of Science:

  • Pediatric healthcare economics
  • Vaccine financing
  • Health services research

Background:

  • Combination vaccines offer convenience but may impact provider reimbursement.
  • Understanding financial implications is key for vaccine uptake.
  • Pediarix is a combination vaccine for infants.

Purpose of the Study:

  • To compare provider reimbursement for Pediarix versus equivalent component vaccines.
  • To analyze the financial impact on pediatric providers.
  • To identify potential financial barriers to combination vaccine administration.

Main Methods:

  • Analysis of provider billing data from a remittance service (June 2007-July 2009).
  • Examination of vaccine product to immunization administration (IA) code ratios.
  • Comparison of total charges and payments for Pediarix vs. component vaccines.

Main Results:

  • Providers received $23 less from commercial payers and $13 less from Medicaid for Pediarix.
  • Commercial payments favored age-specific IA codes, while Medicaid favored non-age-specific codes.
  • 76% of claims were adjusted due to exceeding contract arrangements or fee schedules.

Conclusions:

  • Administering combination vaccines leads to reduced provider payments.
  • New immunization administration codes require monitoring to correct financial barriers.
  • Financial incentives may need adjustment to encourage combination vaccine use.